A detailed history of Wellington Management Group LLP transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Wellington Management Group LLP holds 25,345,680 shares of AUTL stock, worth $51.7 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
25,345,680
Previous 24,220,226 4.65%
Holding current value
$51.7 Million
Previous $87.9 Million 32.25%
% of portfolio
0.01%
Previous 0.02%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 12, 2025

BUY
$2.18 - $4.8 $2.45 Million - $5.4 Million
1,125,454 Added 4.65%
25,345,680 $59.6 Million
Q3 2024

Nov 14, 2024

BUY
$3.38 - $4.69 $21.4 Million - $29.7 Million
6,330,392 Added 35.39%
24,220,226 $87.9 Million
Q2 2024

Aug 13, 2024

BUY
$3.33 - $5.68 $23.7 Million - $40.5 Million
7,126,833 Added 66.22%
17,889,834 $62.3 Million
Q1 2024

May 15, 2024

BUY
$5.39 - $7.29 $58 Million - $78.5 Million
10,763,001 New
10,763,001 $68.7 Million

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $185M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Wellington Management Group LLP Portfolio

Follow Wellington Management Group LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.